2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 291-292
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Blood Banking, Cell Expansion, Gene Editing, Profiling, Biological Processes, Genomics, Hematopoiesis, Metabolism, Molecular Biology, Diseases, Genetic Disorders, Metabolic Disorders, Research, Fundamental Science, Translational Research, Study Population, Human, Adult
PAPER

983 Identification of kinase signaling networks and impact of pharmacologic modulation in mature erythrocytes

John Schell, MD, PhD, Lewis Cantley, PhD2
1 Brigham & Women's Hospital, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Introduction

The erythrocyte undergoes extensive remodeling to reach its final state. With the loss of its nucleus, mitochondria, and other organelles, much of the machinery that enables response and adaptation to stress is absent. Despite this, the red cell is subjected to among the most extreme environments of any cell throughout its 120-day lifespan. A key mechanism used to respond to environmental stressors is altered protein function. In part this is mediated by protein kinases that, through the phosphorylation of specific residues, alter protein activity or localization. While recent work has expanded our understanding of kinase signaling during erythropoiesis, far less is known about the critical kinase mediators of stress responses in aged erythrocytes. This work provides among the most complete assessments of phosphorylation and kinase activity in the mature red cell. With specific interest in energy sensing, we employed pharmacologic modulators of AMP-activated protein kinase (AMPK) in the aged red cell.

Methods

Human erythrocytes were provided by the Brigham and Women’s transfusion medicine service. Nutrient activation of fresh washed red cells diluted to a hematocrit of 25% was performed in cell culture media containing 4.5 g/L glucose and 1 mM pyruvate for 3 hours. Phosphoproteomic analysis was performed following lysis in imidazole buffer with protease and phosphatase inhibitors. Culture experiments included the addition of the AMPK inhibitor BAY3827, or AMPK activators 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR), MK8277, and A769662 in 96 well plates. Free hemoglobin was measured by absorbance at 405 nanometers (nm). Adenosine triphosphate (ATP) was measured via luciferase-coupled assay. Reactive oxygen species were measured by 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA). Metabolomics samples were centrifuged and washed twice in cold PBS followed by snap freezing in liquid nitrogen. Glutathione reductase activity assay was performed as previously described.

Results

Phosphoproteomics on 8 biological replicates pre and post nutrient incubation revealed 655 significant differentially phosphorylated peptides of 401 distinct proteins. Enrichment analysis to predict the kinase(s) most likely performing phosphorylation events identified the energy-sensing kinase AMPK including key markers phospho-AMPK alpha threonine-172 and downstream phospho-Raptor serine-792 as enhanced in storage and reduced on nutrient incubation. This pathway was validated by immunoblotting with phospho-Raptor (stored 4.81 vs, media 0.828, p = 0.016).

To determine the impact of AMPK signaling, red cells were treated with AMPK activators AICAR, MK8722 and A769662. Across multiple independent samples, AMPK activation resulted in increased free hemoglobin in supernatant indicating enhanced red cell destruction. Both free hemoglobin and total cell number could be partially rescued by pre-treatment with the AMPK inhibitor BAY3827. Inhibition of AMPK activity alone had no significant impact on red cell homeostasis. BAY3827 pretreatment partially restored ATP level in AICAR treated samples. Measurement of oxidative stress with H2DCFDA showed increased levels in AICAR only samples that was blunted by the inhibitor BAY3827. Metabolomic analysis showed that the levels of reduced glutathione (glutathione-NEM) within AICAR treated cells were significantly reduced while oxidized glutathione (GSSG) increased compared to control (Glutathione-NEM control 3.85 vs AICAR 0.807, p = 0.002, GSSG control 6.44 vs AICAR 71.57, p < 0.0001). Glutathione reductase activity assay revealed AICAR treated erythrocytes displayed significantly reduced activity compared to control samples (control 2.48 vs AICAR 1.64 Δ340nm/min/ug protein, p = < 0.0001).

Conclusions

AMPK signaling is intact in mature red cells including downstream effectors such as Raptor. Activation of AMPK leads to enhanced destruction that can be partially rescued by the AMPK inhibitor BAY3827 as evidenced by total erythrocyte number and hemoglobin release into supernatant. We have identified alterations in redox handling as a mediator of AICAR induced AMPK activation likely leading to increased red cell destruction. This work defines the impact of extended pharmacologic modulation of AMPK in healthy, aged erythrocytes. Work is underway to identify key AMPK dependent and independent factors that influence erythrocyte homeostasis.

John Schell, MD, PhD: No relevant conflicts of interest to declare.